The NHS is seeking to be among the first health services in the world to adopt ‘tumour agnostic’ drugs, its Chief Executive Simon Stevens announced last week.
NHS England will seek to fast-track the introduction of these drugs once they gain licences, Stevens told the Confed19 conference in Manchester
The first drugs of this kind are NTRK inhibitors, which are currently waiting for EU market authorisation. NTRK fusion mutations are commonly found in a range of rare cancers including salivary tumours, secretory breast cancer and infantile fibrosarcoma – and also less frequently in common cancers. The NTRK fusion accelerates cancer growth, so it is hoped that NTRK inhibitors such as larotrectinib and entrectinib will shri...
1 day ago
The NHS is seeking to be among the first health services in the world to adopt ‘tumour agnostic’ drugs, its Chief Executive Simon Stevens announced last week.
NHS England will seek to fast-track the introduction of these drugs on...
1 day ago
A researcher from the University of Dundee has been given one of five major grants from the charity Cancer Research UK to investigate enzymes thought to promote the development of acute myeloid leukaemia (AML).
Dr Kasper Rasmusse...
4 days ago